Published Aug 23, 2026
DiaMedica Therapeutics: Advancing a First-in-Class Kallikrein Platform Through Dual Clinical Inflections
In-depth research on DMAC covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
4,600 words20 min read
Read report